|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||603.55 - 615.76|
|52-week range||603.55 - 615.76|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||9.81|
|Earnings date||03 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.
Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.